Wikipedia -WSS

Wikipedia

author：explore 2025-09-28 18:31:01 - browse：5752

A product image of the Cue reader COVID-19 home use test — Businesswire via AP

The Food and Drug Administration warned consumers Monday to not use Cue Health’s at-home Covid-19 tests. This follows an FDA warning letter to the company last week that said Cue was not following the conditions stipulated in the emergency use authorizations for its tests.

The FDA letters said the tests could give false results. Specifically, the agency said that the company had changed how the electrochemical signals within the test device were generated, received, and interpreted — changes the FDA has not authorized. These changes decreased the stability of the tests and might lead to false results, the agency said.

The FDA warnings come near what might be the end of a spectacularly bumpy ride for the company. When Cue went public in 2021, it was valued at nearly $3 billion. It supplied tests for the NBA’s 2020 “bubble,” leading a Trump administration official to proclaim that if the test was “good enough for LeBron,” the administration would bring it to the American people — and it did, in a $481 million deal.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Where are patients getting their prescriptions for GLP

focus

explore

WSS

IVG is promising — but it won’t replace IVF quite yet

Pharma budget tightening trickles down to Doximity

White House drug shortages task force keeps mum with Congress

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

TB outbreak tied to bone grafts underscores testing shortcomings

Some of the ways extreme heat will change life as we know it

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Moonlake's readout produced a cash windfall. Risks remain

The biotech scorecard for Q4: 16 stock

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Nobel honors Karikó and Weissman's enduring partnership

DIEP, the 'gold standard' of breast reconstruction, is under threat

Large hospital system sues Multiplan for low

How one medical school became remarkably diverse

Health insurers' Q3 question: how much care are people getting?

What does generative AI mean for health care? We asked experts

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

focus

Genentech weighs delaying cancer therapy after drug pricing law

CRISPR base editing slashes cholesterol levels in monkeys

Large hospital system sues Multiplan for low

The perfect storm of weather conditions that led to the devastating wildfires in Maui

WHO recommends second malaria vaccine

Stop Congress from blocking public access to science

focus

hotspot

explore

knowledge